Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Schizophrenia Age: Adult |
Dose: Oral – 5-10 mg Frequency: once daily Note: Initial dose; if necessary, may be titrated upward in increments of 5 mg/day at intervals greater than 1 week |
|
Indication: Schizophrenia Age: Adult |
Dose: Oral – 10-20 mg Frequency: once daily Note: Maintenance dose; not to exceed 20 mg/day |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Bipolar I Disorder (Manic or Mixed Episodes) Age: less than 13 years |
Dose: Oral – Safety and efficacy not established |
|
Indication: Bipolar I Disorder (Manic or Mixed Episodes) Age: 13-17 years |
Dose: Oral – 2.5-5 mg/day initially; target dosage, 10 mg/day Frequency: once daily Note: by mouth (oral); adjust by increments/decrements of 2.5-5 mg; dosage range, 2.5-20 mg/day |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment |
Dose: Tablet – 5 mg Frequency: once daily Note: Initial dose |
Administration
- May be taken with or without food
- Take at same time each day
Side Effect
- Orthostatic hypotension (More than 20%)
- Weight gain
- dose dependent (5-40%)
- Hypertriglyceridemia (Less than 39%)
- Hypercholesterolemia (Less than 39%)
- Somnolence
- dose dependent (6-39%)
- Extrapyramidal symptoms (EPS)
- dose dependent (15-32%)
- Xerostomia (9-22%)
- Weakness (2-20%)
- Dizziness (4-18%)
- Accidental injury (12%)
- Insomnia (12%)
- Elevated alanine aminotransferase (ALT) level (5-12%)
- Constipation (9-11%)
- Dyspepsia (7-11%)
- Hyperprolactinemia (30%)
- Hyperglycemia (12.8%)
- Hypotension (2%)
- Postural hypotension (1%)
- Tremor (1%)
- Asthenia (2%)
- Akathisia reactions (2%)
- Parkinsonism reactions (4%)
- Syncope
- Sudden cardiac death
- Hyperglycemia
- Diabetic coma with ketoacidosis
- Diabetic ketoacidosis
- Acute hemorrhagic pancreatitis
- Venous thromboembolism
- Immune hypersensitivity reaction
- Cerebrovascular disease
- Seizure
- status epilepticus
- Suicidal intent
- Pulmonary embolism
- Death
- Neuroleptic malignant syndrome (NMS)
- Tardive dyskinesia
- Exacerbation of preexisting diabetes sometimes leading to ketoacidosis
- Neuroleptic malignant syndrome
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Activated charcoal
|
Reduced oral bioavailability of olanzapine by 50-60%
|
|
Levodopa, Dopamine Agonists (Bromocriptine, Pergolide, Ropinirole, Pramipexole)
|
May antagonize effects
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Angle-Closure Glaucoma
|
Can increase eye pressure
|
|
History of CVS Disease (IM)
|
Risk of cardiovascular complications
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Details coming soon
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.